Publications by Arne Kolstad
152 publications found
Original articles
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study
Haematologica, 109 (4), 1171-1183
DOI 10.3324/haematol.2023.283352, PubMed 37646663
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Blood Adv, 8 (2), 407-415
DOI 10.1182/bloodadvances.2023011920, PubMed 38113470
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update
Blood (in press)
DOI 10.1182/blood.2023021567, PubMed 38194692
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Adv, 7 (23), 7216-7230
DOI 10.1182/bloodadvances.2023010158, PubMed 37695745
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma
Blood Adv, 7 (18), 5304-5313
DOI 10.1182/bloodadvances.2023010052, PubMed 37389827
A systematic safety pipeline for selection of T-cell receptors to enter clinical use
NPJ Vaccines, 8 (1), 126
DOI 10.1038/s41541-023-00713-y, PubMed 37607971
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors
Haematologica, 108 (4), 1092-1104
DOI 10.3324/haematol.2022.281420, PubMed 36519324
Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score
Leuk Lymphoma, 64 (8), 1414-1423
DOI 10.1080/10428194.2023.2216819, PubMed 37259807
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL
Leukemia, 36 (12), 2912-2916
DOI 10.1038/s41375-022-01725-8, PubMed 36274067
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
Mol Imaging Biol, 24 (5), 807-817
DOI 10.1007/s11307-022-01731-3, PubMed 35486292
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro
PLoS One, 17 (4), e0267543
DOI 10.1371/journal.pone.0267543, PubMed 35486574
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Br J Haematol, 197 (6), 697-708
DOI 10.1111/bjh.18149, PubMed 35254660
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nat Med, 28 (2), 325-332
DOI 10.1038/s41591-021-01622-0, PubMed 34921238
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Nat Biotechnol, 40 (4), 488-498
DOI 10.1038/s41587-021-01089-x, PubMed 34873326
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
Hematol Oncol, 40 (1), 22-30
DOI 10.1002/hon.2940, PubMed 34713465
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
Virchows Arch, 480 (3), 655-666
DOI 10.1007/s00428-021-03228-w, PubMed 34738194
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Acta Oncol, 60 (11), 1481-1488
DOI 10.1080/0284186X.2021.1959635, PubMed 34425735
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
Cancer Rep (Hoboken), 5 (7), e1524
DOI 10.1002/cnr2.1524, PubMed 34319003
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials
Leukemia, 36 (1), 177-188
DOI 10.1038/s41375-021-01311-4, PubMed 34244612
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Br J Haematol, 193 (3), 520-531
DOI 10.1111/bjh.17366, PubMed 33686666
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
Hemasphere, 5 (1), e510
DOI 10.1097/HS9.0000000000000510, PubMed 33364550
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
BMC Cancer, 20 (1), 1202
DOI 10.1186/s12885-020-07678-4, PubMed 33287742
A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma
Med, 2 (2), 180-195.e5
DOI 10.1016/j.medj.2020.10.006, PubMed 35590201
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Eur J Nucl Med Mol Imaging, 48 (6), 1902-1914
DOI 10.1007/s00259-020-05098-x, PubMed 33196921
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
Br J Haematol, 191 (5), 796-805
DOI 10.1111/bjh.17023, PubMed 32748433
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
Blood, 135 (22), 2000-2004
DOI 10.1182/blood.2019003539, PubMed 32181815
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
PLoS One, 15 (3), e0230526
DOI 10.1371/journal.pone.0230526, PubMed 32187209
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Haematologica, 105 (6), 1604-1612
DOI 10.3324/haematol.2018.214056, PubMed 31537689
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
DOI 10.1007/s00259-019-04417-1, PubMed 31309259
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Lancet Haematol, 5 (3), e109-e116
DOI 10.1016/S2352-3026(18)30018-8, PubMed 29396091
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Blood, 130 (17), 1903-1910
DOI 10.1182/blood-2017-04-779736, PubMed 28819011
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years
Hematol Oncol, 36 (1), 217-223
DOI 10.1002/hon.2415, PubMed 28393375
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
Cytometry B Clin Cytom, 92 (1), 79-87
DOI 10.1002/cyto.b.21498, PubMed 27933753
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Biol Blood Marrow Transplant, 23 (3), 428-435
DOI 10.1016/j.bbmt.2016.12.634, PubMed 28039078
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
Blood, 129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
Immunology, 149 (1), 62-73
DOI 10.1111/imm.12629, PubMed 27278254
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
Leuk Lymphoma, 58 (3), 623-632
DOI 10.1080/10428194.2016.1204653, PubMed 27389974
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Br J Haematol, 175 (3), 410-418
DOI 10.1111/bjh.14241, PubMed 27378674
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
Blood, 128 (14), 1814-1820
DOI 10.1182/blood-2016-03-704023, PubMed 27354719
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years
PLoS One, 10 (7), e0131158
DOI 10.1371/journal.pone.0131158, PubMed 26147646
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator
Blood, 125 (17), 2669-77
DOI 10.1182/blood-2014-06-584193, PubMed 25736311
Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma
Biol Blood Marrow Transplant, 21 (5), 840-7
DOI 10.1016/j.bbmt.2014.12.027, PubMed 25689789
Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
Histopathology, 67 (1), 62-9
DOI 10.1111/his.12624, PubMed 25431344
Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma
Blood, 125 (1), 82-9
DOI 10.1182/blood-2014-07-592162, PubMed 25293773
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study
Br J Haematol, 166 (1), 98-108
DOI 10.1111/bjh.12854, PubMed 24684350
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Blood, 123 (19), 2953-9
DOI 10.1182/blood-2013-12-541953, PubMed 24652994
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
Leuk Lymphoma, 55 (10), 2319-27
DOI 10.3109/10428194.2013.871632, PubMed 24432894
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
Blood, 121 (8), 1367-76
DOI 10.1182/blood-2012-04-421826, PubMed 23297127
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma
Anticancer Res, 33 (1), 85-95
PubMed 23267131
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Ann Oncol, 24 (5), 1385-92
DOI 10.1093/annonc/mds621, PubMed 23247661
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
BMC Cancer, 12, 478
DOI 10.1186/1471-2407-12-478, PubMed 23072591
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
Br J Haematol, 158 (3), 355-62
DOI 10.1111/j.1365-2141.2012.09174.x, PubMed 22640180
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-71
DOI 10.1182/blood-2011-08-372649, PubMed 22058114
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-1259
DOI 10.1093/annonc/mdr385, PubMed 21926399
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells
Int J Cancer, 130 (8), 1821-32
DOI 10.1002/ijc.26209, PubMed 21630262
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
Blood, 118 (11), 3088-95
DOI 10.1182/blood-2011-03-343434, PubMed 21791422
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study
Br J Haematol, 152 (5), 600-10
DOI 10.1111/j.1365-2141.2010.08519.x, PubMed 21241276
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Blood, 115 (8), 1530-3
DOI 10.1182/blood-2009-08-236570, PubMed 20032504
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma
J Clin Oncol, 27 (26), 4365-70
DOI 10.1200/JCO.2008.21.3116, PubMed 19652064
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Blood, 114 (16), 3431-8
DOI 10.1182/blood-2009-05-223958, PubMed 19641184
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
J Clin Oncol, 26 (32), 5156-64
DOI 10.1200/JCO.2008.17.2015, PubMed 18854568
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
Ann Oncol, 19 (11), 1935-40
DOI 10.1093/annonc/mdn404, PubMed 18684698
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Blood, 112 (7), 2687-93
DOI 10.1182/blood-2008-03-147025, PubMed 18625886
Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies
Virchows Arch, 450 (5), 559-65
DOI 10.1007/s00428-007-0407-6, PubMed 17406891
Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
Leuk Lymphoma, 48 (3), 570-6
DOI 10.1080/10428190601126610, PubMed 17454601
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
Biol Blood Marrow Transplant, 12 (11), 1150-60
DOI 10.1016/j.bbmt.2006.06.015, PubMed 17085308
131I-tositumomab therapy as initial treatment for follicular lymphoma
N Engl J Med, 352 (5), 441-9
DOI 10.1056/NEJMoa041511, PubMed 15689582
[Should complementary therapies be offered in hospitals?]
Tidsskr Nor Laegeforen, 124 (23), 3078-80
PubMed 15586193
The Patient Experiences Questionnaire: development, validity and reliability
Int J Qual Health Care, 16 (6), 453-63
DOI 10.1093/intqhc/mzh074, PubMed 15557355
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway
Eur J Cancer, 40 (4), 529-35
DOI 10.1016/j.ejca.2003.11.011, PubMed 14962719
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway
Support Care Cancer, 12 (5), 312-8
DOI 10.1007/s00520-004-0590-9, PubMed 14767750
[Should alternative therapists treat cancer--what is the opinion of oncology health personnel?]
Tidsskr Nor Laegeforen, 123 (21), 3059-61
PubMed 14618177
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant
Eur J Haematol, 71 (2), 73-80
DOI 10.1034/j.1600-0609.2003.00093.x, PubMed 12890145
[Alternative medicine--attitudes and use among physicians, nurses and administrative staff employed in hospitals in northern Norway]
Tidsskr Nor Laegeforen, 123 (5), 604-6
PubMed 12683182
[Mental distress and use of alternative medicine among cancer patients]
Tidsskr Nor Laegeforen, 123 (5), 607-9
PubMed 12683183
Structure of conduct problems in adolescence
Scand J Psychol, 43 (1), 81-91
DOI 10.1111/1467-9450.00271, PubMed 11885763
Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae
Med Oncol, 19 (2), 71-8
DOI 10.1385/MO:19:2:71, PubMed 12180483
Use of alternative medicine among Norwegian cancer patients is associated with mental distress--a follow-up study
Acta Oncol, 41 (7-8), 646-51
PubMed 14651209
Use of Alternative Medicine Among Norwegian Cancer Patients is Associated with Mental Distress - A Follow-up Study
Acta Oncol, 41 (7-8), 646-651
DOI 10.1080/028418602321028265, PubMed 28758867
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines
Bone Marrow Transplant, 28 (7), 681-7
DOI 10.1038/sj.bmt.1703228, PubMed 11704791
Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
Clin Immunol, 100 (1), 40-8
DOI 10.1006/clim.2001.5050, PubMed 11414744
The South Asian cataract management study: complications, vision outcomes, and corneal endothelial cell loss in a randomized multicenter clinical trial comparing intracapsular cataract extraction with and without anterior chamber intraocular lens implantation
Ophthalmology, 107 (2), 231-40
DOI 10.1016/s0161-6420(99)00008-1, PubMed 10690817
Adolescent alcohol abstainers: Traditional patterns in new groups
Acta Sociol., 43 (3), 219-233
DOI 10.1177/000169930004300303
Persistent changes in the immune system 4-10 years after ABMT
Bone Marrow Transplant, 24 (8), 873-8
DOI 10.1038/sj.bmt.1702006, PubMed 10516699
Opinions on and use of alternative medicine among physicians, nurses and clerks in northern Norway
In Vivo, 13 (6), 493-8
PubMed 10757043
[Decentralized high-dose cytostatic treatment with autologous stem cell support]
Tidsskr Nor Laegeforen, 118 (18), 2777-80
PubMed 9748807
H-1 NMR study on the interaction between trans-Cl2Pd(dipeptide)(2) (dipeptide is glyglyOH and gly-L-nvalOH) and the dodecanucleotide [d(CGCGAATTCGCG)](2)
J. Inorg. Biochem., 70 (3-4), 265-269
DOI 10.1016/S0162-0134(98)10026-0
Risk perception related to depletion of the ozone layer and UV-B radiation in the arctic
Int J Circumpolar Health, 57 Suppl 1, 596-600
PubMed 10093349
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
Tidsskr Nor Laegeforen, 116 (21), 2547-51
PubMed 8928122
Sequence-selective interaction between mercury(II) ions and the DNA dodecamer [d(GCCGATATCGGC)]2 studied by 1H NMR spectroscopy
Acta Chem Scand (Cph), 50 (9), 775-82
DOI 10.3891/acta.chem.scand.50-0775, PubMed 8817868
Imprisonment as rehabilitation: Offenders' assessment of why it does not work
J. Crim. Justice, 24 (4), 323-335
DOI 10.1016/0047-2352(96)00020-7
Mapping of an epitope defined by a human hybridoma antibody (TrD3): a new HLA-B supertype associated with a subset of HLA-Bw6
Hum Immunol, 34 (2), 77-84
DOI 10.1016/0198-8859(92)90032-i, PubMed 1385373
Children's symptoms and items of behaviour. An epidemiological study of sociocultural aetiology
Acta Paedopsychiatr, 55 (2), 77-82
PubMed 1585805
[Assessment and quality assurance of medical technology--Scandinavian cooperation]
Nord Med, 106 (2), 61-4
PubMed 2006098
A supertypic HLA-DP specificity defined by two human-human hybridoma antibodies (TrB50; TrE11)
Hum Immunol, 25 (4), 247-56
DOI 10.1016/0198-8859(89)90087-6, PubMed 2788637
A cytotoxic human-human hybridoma antibody (TrC7) specific for HLA-A29
Tissue Antigens, 33 (5), 542-5
DOI 10.1111/j.1399-0039.1989.tb01705.x, PubMed 2552611
Multiple sclerosis patients have a high frequency of an HLA-DQ beta epitope defined by a human-human hybridoma antibody
Tissue Antigens, 33 (5), 546-9
DOI 10.1111/j.1399-0039.1989.tb01706.x, PubMed 2477915
Two HLA-DQ-specific human-human hybridoma antibodies (TrG6;TrC5) define epitopes also expressed by a transcomplementing hybrid DQ molecule (DQw7 alpha/DQw4 beta)
Hum Immunol, 24 (1), 15-29
DOI 10.1016/0198-8859(89)90043-8, PubMed 2464569
Evaluation of medical equipment on the basis of users' experiences and hazard registration
Health Policy, 11 (1), 61-72
DOI 10.1016/0168-8510(89)90056-0, PubMed 10292207
[Where ought psychiatric patients be placed? A survey of ideal and realistic residential and therapeutic possibilities for patients in psychiatric hospitals]
Tidsskr Nor Laegeforen, 108 (4), 315-8
PubMed 3353927
A cytotoxic human-human hybridoma antibody (TrH6) specific for HLA-DRw52
Tissue Antigens, 31 (2), 90-7
DOI 10.1111/j.1399-0039.1988.tb02069.x, PubMed 2836964
Look to Norway! (But not uncritically)
Int J Technol Assess Health Care, 4 (3), 359-74
DOI 10.1017/s0266462300000325, PubMed 10312679
WHERE DO PSYCHIATRIC-PATIENTS WANT TO STAY
Nord. Psykol., 40 (3), 161-170
DOI 10.1080/00291463.1988.10636920
A human-human hybridoma (Tr7E2) producing cytotoxic antibody to HLA-DQw1
Hum Immunol, 20 (4), 307-20
DOI 10.1016/0198-8859(87)90021-8, PubMed 2449413
A human-human hybridoma antibody (TrB12) defining subgroups of HLA-DQw1 and -DQw3
Hum Immunol, 20 (3), 219-31
DOI 10.1016/0198-8859(87)90105-4, PubMed 2830209
A human-human hybridoma producing cytotoxic antibody to HLA-B15, cross-reacting with B17, B5, B35 and B18
Tissue Antigens, 29 (5), 246-56
DOI 10.1111/j.1399-0039.1987.tb01584.x, PubMed 2821654
Antibodies to granulocytes detected by an indirect immunofluorescence method not requiring chemical modification of cells
Transfusion, 25 (2), 165-9
DOI 10.1046/j.1537-2995.1985.25285169213.x, PubMed 3885485
EPIDEMIOLOGY OF BLINDNESS IN NEPAL
Bull. World Health Organ., 63 (2), 375-386
Epidemiology of blindness in Nepal
Bull World Health Organ, 63 (2), 375-86
PubMed 3874717
Review articles
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update
Semin Nucl Med, 53 (3), 413-425
DOI 10.1053/j.semnuclmed.2022.12.006, PubMed 36635112
Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
Leuk Lymphoma, 50 (8), 1249-56
DOI 10.1080/10428190903040030, PubMed 19562619
Other articles
MetaGate: Interactive Analysis of High-Dimensional Cytometry Data with Meta Data Integration
bioRxiv
DOI 10.1101/2023.10.27.564454, PubMed 37961421
Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials
Leukemia, 36 (4), 1198
DOI 10.1038/s41375-022-01526-z, PubMed 35181760
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Haematologica, 103 (11), e541-e543
DOI 10.3324/haematol.2018.194399, PubMed 29794145
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
Leukemia, 30 (6), 1428-30
DOI 10.1038/leu.2015.322, PubMed 26598017
"In situ" vaccination for systemic effects in follicular lymphoma
Oncoimmunology, 4 (7), e1014773
DOI 10.1080/2162402X.2015.1014773, PubMed 26140239
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
Leuk Lymphoma, 55 (5), 1206-8
DOI 10.3109/10428194.2013.825906, PubMed 23876100
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
Br J Haematol, 159 (5), 604-8
DOI 10.1111/bjh.12073, PubMed 23043253
Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Br. J. Haematol., 158 (6), 815-816
DOI 10.1111/bjh.12006
[Can the immune system target cancer?]
Tidsskr Nor Laegeforen, 132 (7), 784-5
DOI 10.4045/tidsskr.12.0156, PubMed 22511078
High frequency of unrecognized indolent hematological disorders among HLA-matched siblings of patients with lymphoproliferative malignancies eligible for allo-SCT
Bone Marrow Transplant, 42 (6), 427-8
DOI 10.1038/bmt.2008.183, PubMed 18587433
[Heart complications following cancer treatment]
Tidsskr Nor Laegeforen, 128 (2), 187-8
PubMed 18240394
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
Haematologica, 92 (1), 139-40
DOI 10.3324/haematol.10564, PubMed 17229653
Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products
Transfusion, 44 (6), 942-3
DOI 10.1111/j.1537-2995.2004.00379.x, PubMed 15157265
Persistent immunological changes 55 months after PBPCT. Is the restoration of immune function possible with a longer follow-up? Response
Bone Marrow Transplant., 26 (6), 708
DOI 10.1038/sj.bmt.1702605
JACK PLUS JILL EQUALS TROUBLE - YOUNG-PEOPLE AND SEX - NORWEGIAN - ERICSSON,K, LUNDBY,G, RUDBERG,M
Nord. Psykol., 39 (1), 71-73
VIOLENCE AND CONFLICTS WITH ANIMALS AND MAN - NORWEGIAN - BJERKE,T
Nord. Psykol., 38 (3), 233-235
Books
Effekt av aktiv sykemelding, 2002-2003
In Rapport, Utredningsavdelingen, [Oslo], 03/2004, 23 s.
BIBSYS 041696573
Effekt av aktiv sykmelding?
In Rapport, Utredningsavdelingen, [Oslo], 10/2003, 57 s.
BIBSYS 041593731
Effects of changing government policies on sickness absence behaviour
In NOVA-rapport, Norsk institutt for forskning om oppvekst, velferd og aldring, Oslo, 14/99, 44 s.
BIBSYS 000108804, ISBN 82-7894-083-5
Changing classes: stratification and mobility in post-industrial societies
International Sociological Association, London, IX, 261 s.
BIBSYS 931094062, ISBN 0-8039-8896-6
Rapport fra rusmiddelundersøkelsen 1987
Bodø, 46 s.
BIBSYS 920681905
Fiskernes trygdemessige status og sosiale ordninger ; Frafiskesesong til sykepengesesong?
In Rapport, Nordlandsforskning, Bodø, 12/88, 29 s.
BIBSYS 900029722
Book chapters
Norge for nordmenn?
In Samfunnsspeilet, Statistisk sentralbyrå, Oslo, 9(1995)nr 2, S. 47-52
BIBSYS 032145764
Theses
Variants of HLA antigens defined by human-human hybridomaantibodies
Intitute of Medical Biology, University of Tromsø, Tromsø, 1 b. (flere pag.)
BIBSYS 890075492